ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to...
Read More
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19

Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. We’ve made...
Read More
ICYMI: New report demonstrates growing global impact of antimicrobial resistance

New research published in The Lancet shows for the first time the global impact of antimicrobial resistance (AMR), which poses an increasingly serious threat to human health around the world. The...
Read More
Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance

COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract. Over the past 100 years, pandemics have been caused by novel forms of influenza and other...
Read More
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging

The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened by...
Read More
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response

As America’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen...
Read More
The next threat: Combatting antimicrobial resistance

Since their discovery, antimicrobial medicines have revolutionized the fight against disease and today represent one of the greatest achievements in public health. But after decades of helping to...
Read More
New initiative to bridge the gap on antimicrobial innovation

Today, more than 20 leading biopharmaceutical companies are launching the AMR Action Fund, a ground-breaking partnership to invest nearly $1 billion to ensure a robust and diverse pipeline of new...
Read More